To describe lecanemab patient profile and utilization patterns in real-world settings.

Lecanemab is the first anti-amyloid monoclonal antibody to receive full approval in the United States for early Alzheimer’s disease (AD).

This retrospective study used open and closed claims from the Komodo Research Database. Patients with ≥1 lecanemab claims, and continuous enrollment or clinical activity ≥12 months prior to the first lecanemab administration were included. Observation period ran from the first lecanemab administration to latest clinical activity (open claims) or end of health plan enrollment (closed claims). Persistence to lecanemab was defined as the absence of any interval of >90 days between consecutive infusions. Kaplan-Meier analysis was used to report persistence. More recent data will be presented at the congress.

A total of 3,155 patients initiating lecanemab (01Jan2023-30Jun2024) met the inclusion criteria. Mean observation period was 129.1 (standard deviation [SD] 91.1) days. Over 90% of these patients initiated lecanemab in or after October 2023. Mean age was 75.0 (SD 6.8) years, 55.8% were female, 84.3% White, 89.4% Medicare beneficiaries, and 93.3% received infusions in urban settings. In the 12 months prior to lecanemab initiation, 60.8% and 83.8% of patients had a diagnosis of mild cognitive impairment and AD, respectively, and 3.7% of patients were using anticoagulant medications. Among each patient with ≥2 lecanemab claims, the average number of lecanemab administrations per month was 1.9 (SD 0.7), with 16.5 (SD 9.2) days between consecutive administrations. Time to first head MRI post lecanemab initiation was 46.7 (SD 23.4) days. Persistence to lecanemab treatment was 85.1% at 4 months of follow-up.

Lecanemab appeared to be utilized in appropriate patient populations within the dosing and monitoring guidelines in the FDA approved label. Access in rural settings and limited use in minorities may require pathways and outreach programs to close these gaps.